chris thompson
-
Astellas to sale off the Oncology line by 2015
Despite success of Xtandi in prostate cancer market, Astellas leadership is planing to sell the rights for Tarceva, Xtandi and other marketed Oncology products to raise money for the upcoming merger in 2015. The action is supported by lack of Oncology pipeline activities in clinical...- Anonymous
- Thread
- chris thompson
- Replies: 66
- Forum: Astellas